$CNO

9,336-share cashout at CNO Financial (NYSE: CNO) follows $515,366 stock sale

CNO Financial Group (CNO) disclosed that officer Karen DeToro plans to sell 9,336 shares of CNO common stock, valued at $511,002.96 as of September 1, 2026. The planned sales include 1,836 restricted shares and 7,500 shares from a stock option exercise. DeToro also reported a prior sale of 9,374 shares on August 31, 2026 for $515,366.21.

Original reporting
Published Sep 1, 2026, 8:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2026, 5:44 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CNO
Neutral
high confidence
Mentioned
$CNO
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CNONeutralLow
01

Why it matters

The disclosed sale adds a modest amount of shares to the market, unlikely to affect price materially, but provides transparency for investors.

02

Market read

Routine insider sale with limited trading relevance; primarily of interest to existing shareholders and compliance monitors.

03

What to watch

Potential upcoming earnings or strategic announcements that may amplify the impact of the insider sale.

Relevance 4/10Novelty 4/10Timing: September 1, 2026 (filing date)

Background

Form 144 filing by a CNO officer discloses planned insider sales, a standard regulatory requirement for restricted shares.

Company-level read

Ticker impact

$CNONeutralHigh confidence
Context

Officer Karen DeToro filed a Form 144 to sell 9,336 CNO shares worth $511,003, after a prior sale of 9,374 shares for $515,366.

Expected impact

Minimal short‑term impact; price likely to stay within current range.

Evidence & confidence

The transaction size (~$0.5 M) is small relative to CNO's market cap and typical daily volume, so any price effect will be limited.

Market effects

None; the sale is company‑specific and does not affect the broader financial services sector.

No regional effect; the filing is a routine insider transaction.

Low; limited to CNO shareholders.

Counterpoint

If the insider is reducing exposure, it could signal concerns about near‑term performance, warranting a closer look.

Key entities

  • CNO Financial Group, Inc.

    US‑listed insurer and financial services firm (ticker CNO).

  • Karen DeToro

    Officer of CNO filing the Form 144 sale.

Related articles

$CNOMed

CNO Financial Group (CNO) Beats In Q2 But Is The Rally Already Priced In

CNO Financial Group (CNO) reported Q2 revenue beating expectations, with operating earnings per share up 45% and 16 consecutive quarters of sales growth. The stock is up 30.19% year-to-date and 42.14% over one year. However, it is slightly overvalued according to a narrative fair value of $53.50. Growth is driven by annuity and life/health policy sales, digital channels, and an aging U.S. population. Risks include low long-term interest rates and rising long-term care claims.

$CNOMed

California Nanotechnologies Posts 28% Revenue Growth in Q1 FY2027 as Nuclear Pivot Takes Hold

California Nanotechnologies (TSXV:CNO) reported Q1 FY2027 revenue of $917,854, up 28% from $716,553 a year earlier, for the quarter ended May 31, 2026. Adjusted EBITDA loss narrowed to $129,031 from $152,707, while net loss was $449,598. The company attributes growth to customer diversification and a nuclear supply-chain pivot tied to initial SMR component purchase orders.

$CNOHighAI 9/10

CNO Financial (CNO) Q2 2026 Earnings Call Transcript

CNO Financial Group (NYSE:CNO) reported Q2 2026 operating EPS of $1.26, up 45% year over year, and net operating income of $119.5 million. Total new annualized premiums rose 7% to a record. Full-year EPS guidance was raised to $4.60 to $4.80. The company also repurchased $60 million of shares.

$CNOMed

CNO Financial posts insurance income gain on 16-quarter sales streak

CNO Financial Group reported Q2 2026 sales growth for a 16th consecutive quarter. Insurance policy income rose to $680.7 million from $651.3 million a year earlier, and net income increased to $125.9 million, or $1.33 per diluted share, from $91.8 million, or $0.91. CNO raised full-year 2026 operating EPS guidance by 8% at the midpoint and estimated RBC at 377% as of June 30.

$CNOMed

CNO Financial Group’s (NYSE:CNO) Q2 CY2026 Sales Beat Estimates

Insurance services company CNO Financial Group (NYSE: CNO) announced better-than-expected revenue in Q2 CY2026, with sales up 34.6% year on year to $1.29 billion. Its GAAP profit of $1.33 per share was 36.4% above analysts’ consensus estimates. Is now the time to buy CNO Financial Group? Find out by accessing our full research report, it’s free.

$CNOLow

CNO Financial Group, Inc. (CNO): Results of Operations and Financial Condition

CNO Financial Group, Inc. (CNO) filed an SEC Form 8-K — Results of Operations and Financial Condition. News For Immediate Release CNO Financial Group Reports Second Quarter 2026 Results Carmel, Ind., July 30, 2026 - CNO Financial Group, Inc. (NYSE: CNO) today reported its second quarter 2026 financial results: • Strong execution and momentum continues; Raising 2026 operating earni